Roth Capital Partners Announces the Addition of Benjamin E. Paluch, Ph.D. and Boobalan Pachaiyappan, Ph.D. to its Healthcare Research Team
July 08 2024 - 9:00AM
Business Wire
Roth Capital Partners (“ROTH”), www.roth.com, today announced
that Dr. Benjamin E. Paluch and Dr. Boobalan Pachaiyappan have
joined the firm’s healthcare research team, both covering the
biotechnology sector. Dr. Paluch has over four years of
biotechnology equity research experience across a range of
therapeutic areas including oncology and immunology. Dr.
Pachaiyappan’s sell-side experience spans five years, with a focus
on neurology, neuropsychiatry, neuromuscular disorders and
pain.
Prior to joining ROTH, Dr. Paluch specialized in biotechnology
working most recently as an Associate at Robert W. Baird from
2021-2024. He began his equity research career in 2020 as a Senior
Associate at Citigroup. Dr. Paluch received his Ph.D. in Molecular
Pharmacology and Cancer Therapeutics from the University at Buffalo
in 2016. He completed his Ph.D. research at Roswell Park
Comprehensive Cancer Center in Buffalo, NY. He has published
several peer-reviewed articles in high-impact journals (Clinical
Cancer Research, Blood Reviews, Oncotarget and others) and was
twice awarded Young Investigator Travel Awards to present his work
at the Society of Hematologic Oncology annual meetings. After
completing his Ph.D., he worked in a variety of roles gaining
valuable experience in Research & Development, medical affairs,
business development and technology transfer.
Dr. Pachaiyappan embarked on his Equity Research career as an
Associate at H.C. Wainwright and quickly advanced to Vice President
and Director roles. At H.C. Wainwright, he contributed
significantly to 40 initiation reports, holding primary/co-primary
responsibility for 20 stocks. He was awarded a Ph.D. in Medicinal
Chemistry (University of Illinois at Chicago) and an M.S. in
Chemistry (Virginia Tech). His scientific work has been featured in
14 peer-reviewed scientific journals and/or industry magazines, and
he was a co-inventor of a World Patent. During his academic
research career, he received several awards, including the Robert
M. Scarborough Award for Post-Graduate Excellence in Medicinal
Chemistry (American Chemical Society) and the Outstanding Young
Investigator award (Alzheimer's Drug Discovery Foundation).
Jeff Martin, CFA, Co-Director of Research, commented, “I’m
pleased to welcome Ben and Boobalan to our biotechnology research
team. I am confident their strong scientific background and
understanding of the equity markets in biotechnology will serve our
clients well.”
“We are committed to expanding our research department across
industries and market caps,” said Byron Roth, Executive Chairman of
ROTH. “I’m confident that Ben’s and Boobalan’s expertise will
provide valuable insights for our clients and help build upon our
long track record in the Healthcare sector.”
Dr. Paluch commented, “I am thrilled to join ROTH and work on
the Healthcare Research team. My goal is to identify promising
companies that are developing new treatments for underserved
diseases with asymmetric upside for investors.”
Dr. Pachaiyappan commented, “I truly appreciate the opportunity
to join alongside the 218 colleagues at ROTH to add value to
investors, clients and the firm. Given that SMid-cap biotech stocks
are on the cusp of a breakout to the upside, I intend to take a
‘science-first’ approach to identify securities that hold
therapeutic promise yet are flying under the radar and recommend
them to our valued clients.”
Since 2010, ROTH has been involved in over 590 transactions for
its Healthcare clients, with a total transaction value of over
$25.1 Billion. (Source: ROTH 07/02/2024)
About ROTH
Roth Capital Partners, LLC ("ROTH") is a relationship-driven
investment bank focused on serving growth companies and their
investors. Our full-service platform provides capital raising, high
impact equity research, macroeconomics, sales and trading,
technical insights, derivatives strategies, M&A advisory, and
corporate access. Headquartered in Newport Beach, California, ROTH
is a privately-held, employee owned organization and maintains
offices throughout the U.S. For more information on ROTH, please
visit www.roth.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240708476348/en/
Investor and Media Contact: ROTH, Isabel Mattson-Pain, Managing
Director and Chief Marketing Officer, imattson-pain@roth.com,
949-720-7117